For HR+, HER2– node-positive early breast cancer with a high-risk of coming back, as determined by your healthcare provider,
Verzenio is now approved in combination with hormone therapy.
Finally, treatment is moving forward, just like you. Verzenio is the first and only treatment in over 15 years to reduce the risk of recurrence in HR+, HER2– high-risk early breast cancer, when added to hormone therapy.
What is Verzenio?
Verzenio in addition to your hormone therapy (tamoxifen or an aromatase inhibitor) can reduce your risk of recurrence vs hormone therapy alone.
Verzenio was studied in a clinical study of 5637 adults, most of whom were women, with HR+, HER2–, node-positive early breast cancer with a high risk of coming back who had previously received primary treatment. In this study, 2808 patients were treated with Verzenio 150mg orally twice a day plus standard hormone therapy for 2 years, and then hormone therapy alone; 2829 patients received standard hormone therapy alone. The approval was based on a smaller group of 2003 patients from this study.
The recommended dose of Verzenio in combination with hormone therapy is 150 mg by mouth twice a day, taken once in the morning and once at night.
- Each pack contains your dose of 150-mg tablets for 7 days (14 individual 150-mg tablets)
- Multiple tablet strengths (50 mg, 100 mg, and 150 mg) allow your doctor to make dose adjustments based on how you tolerate the drug.
- No matter what dose is prescribed, you will take 1 tablet, 2 times a day, unless your doctor tells you otherwise.
Results with Verzenio + hormone therapy
In a clinical study, Verzenio + hormone therapy was evaluated in mostly women with HR+, HER2– early breast cancer with a high risk of recurrence based on extent of nodal involvement, tumor size, tumor grade, and signs that the tumor was growing quickly.
Protection against risk of recurrence
Verzenio + hormone therapy showed a 37% reduction in the risk of cancer returning compared with hormone therapy alone.
In a study, 86.1% of mostly women taking Verzenio + hormone therapy were alive without their cancer returning vs 79% taking hormone therapy alone. Clinical trials are still ongoing to see if there is a survival benefit.
SELECT SAFETY INFORMATION
Verzenio may cause serious side effects, including:
Diarrhea is common with Verzenio, may be severe and may cause dehydration or infection. The most common time to develop diarrhea is during the first month of Verzenio treatment. If you develop diarrhea during treatment, your healthcare provider may tell you to temporarily stop taking it, stop your treatment, or decrease your dose. If you have any loose stools, start taking an antidiarrheal medicine (such as loperamide), drink more fluids, and tell your healthcare provider right away.
Now there's an opportunity to reduce the risk of cancer returning with Verzenio when added to hormone therapy.
What makes Verzenio different?
Verzenio has already treated over 15,000 patients in the U.S. with certain types of HR+, HER2– metastatic breast cancer, and is now FDA approved to treat patients with HR+, HER2–, node-positive, early breast cancer with a high risk of coming back, in combination with hormone therapy.
Verzenio is a first-of-its-kind treatment designed to further reduce the risk of cancer recurrence when added to hormone therapy vs hormone therapy alone.
Verzenio is a tablet and not an infusion. This means you do not need to go to your doctor's office for this treatment. However, you may need to see your doctor for other treatments or tests. You can take Verzenio in your own home, which could give you more flexibility in your daily life.
How Verzenio works
Watch a video to learn more about how Verzenio works inside the body
